文献速递肿瘤 PET/CT

谦逊的一课:PET-MRI 在检测肝脏恶性病灶方面相对于 PET-CT 的附加价值

A lesson in humility: the added values of PET-MRI over PET-CT in detecting malignant hepatic lesions.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-01-05

该前瞻性研究纳入 61 例患者共 97 对全身 PET-CT 与肝脏 PET-MRI 扫描,评估 PET-MRI 较 PET-CT 在检测活动性肝脏恶性病灶中的附加价值。PET-MRI 在 37/97(38.1%)例中检出 78 个 PET-CT 未显示的恶性病灶,并在 11/97(11.3%)例中显著改变最终报告结论。

要点

  • PET-MRI 在 37/97(38.1%)例中检出 PET-CT 未显示的 78 个肝脏恶性病灶。
  • 78 个病灶中 19 个仅 PET 检出、37 个 ≤0.8 cm 仅 MRI 检出、22 个 >0.8 cm 且 FDG 低/无摄取但 MRI 判为存活。
  • PET-MRI 的额外发现使 11/97(11.3%)例最终报告结论发生重大改变。

核心结论

  • PET-MRI 在评估肝脏恶性受累范围及治疗反应方面较 PET-CT 具有多项优势。
  • PET-MRI 检出的额外恶性病灶归因于更优的 PET 性能、MRI 提供的更高空间分辨率及改进的多参数存活评估。
  • 约十分之一的病例中,PET-MRI 而非 PET-CT 的发现显著改变了最终报告结论。

研究设计与样本

  • 本机构正在进行的评估 PET-MRI 附加价值的前瞻性研究的一部分,受试者在单次放射性示踪剂注射后接受 PET-CT 及随后的 PET-MRI。
  • 纳入 61 例患者的 97 对全身 PET-CT 与肝脏 PET-MRI 扫描,其中 19/61 例有≥2 对配对扫描,全部使用[18F]FDG 并判读为显示活动性肝脏恶性受累。
  • 原发恶性肿瘤来源为结直肠/胆道/胰腺/乳腺/其他,分别为 19/9/9/7/17 例。
  • 86/97 例的检查指征为监测治疗反应。

主要发现

  • 37/97(38.1%)例中,PET-MRI 检出而 PET-CT 未检出的恶性病灶共 78 个。
  • 78 个病灶中,19 个(11 例)在 PET-MRI 的 PET 上检出而 PET-CT 的 PET 未检出。
  • 37 个病灶(14 例)较小(≤0.8 cm),仅 MRI 检出。
  • 22 个病灶(12 例)>0.8 cm,[18F]FDG 摄取低/无,但基于 MRI 归类为存活。
  • 这些 78 个病灶在 11/97(11.3%)例中对最终报告产生重大影响,改变了报告的反应评估分类(10/86 例)或在分期/再分期扫描中定义了肝脏恶性病变(1/11 例)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The recent introduction of integrated PET-MRI systems into practice seems promising in oncologic imaging, and efforts are made to specify their added values. The current study evaluates the added values of PET-MRI over PET-CT in detecting active malignant hepatic lesions. METHODS: As part of an ongoing prospective study in our institution that assesses the added values of PET-MRI, subjects undergo PET-CT and subsequent PET-MRI after single radiotracer injection. The current study included 97 pairs of whole-body PET-CT and liver PET-MRI scans, of 61 patients (19/61 had ≥ 2 paired scans), all performed with [18F]FDG and interpreted as showing active malignant hepatic involvement. Primary malignancies were of colorectal/biliary/pancreatic/breast/other origins in 19/9/9/7/17 patients. Monitoring response to therapy was the indication in 86/97 cases. When PET-MRI detected additional malignant lesions over PET-CT, lesions size, their characteristics on PET-MRI, and the influence on the final report were recorded. RESULTS: In 37/97 (38.1%) cases, a total of 78 malignant lesions were identified on PET-MRI but not on PET-CT: 19 lesions (11 cases) were identified on PET of PET-MRI but not on PET of PET-CT; 37 lesions (14 cases) were small (≤ 0.8 cm) and identified on MRI only; 22 lesions (12 cases) were > 0.8 cm, had low/no [18F]FDG uptake, but were categorized as viable based on MRI. These 78 lesions caused major effect on final reports in 11/97 (11.3%) cases, changing reported response assessment category (10/86 cases) or defining malignant hepatic disease on staging/restaging scans (1/11 cases). CONCLUSION: PET-MRI offers several advantages over PET-CT in assessing the extent and response to therapy of malignant hepatic involvement. Additional malignant lesions detected on PET-MRI are attributed to superior PET performance (compared with PET of PET-CT), greater spatial resolution provided by MRI, and improved multi-parametric viability assessment. In around one-tenth of cases, findings identified on PET-MRI but not on PET-CT significantly change the final report's conclusion.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cohen D, Kesler M, Muchnik Kurash M, et al. A lesson in humility: the added values of PET-MRI over PET-CT in detecting malignant hepatic lesions. Eur J Nucl Med Mol Imaging. 2023. PMID: 36602558. doi:10.1007/s00259-022-06099-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。